Habitat imaging on contrast-enhanced magnetic resonance imaging predicts early response to transarterial chemoembolization in hepatocellular carcinoma

Figure 1 Enrollment and exclusion flowchart of patients with hepatocellular carcinoma. The left side shows the screening process for institution A, where 1631 initial patients with hepatocellular carcinoma who underwent transcatheter arterial chemoembolization were screened. A total of 153 patients were finally enrolled and divided into an internal training set (n = 107) and an internal validation set (n = 46). The right side shows the screening process for institution B, where 743 initial patients with hepatocellular carcinoma who underwent transcatheter arterial chemoembolization were screened. A total of 70 patients were finally enrolled, serving as the external validation set. HCC: Hepatocellular carcinoma; AASLD: American Association for the Study of Liver Diseases; TACE: Transcatheter arterial chemoembolization; MRI: Magnetic resonance imaging.